TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30758297

Group type: EXPERIMENTAL
Intervention: Near-real-time financial incentives for weight loss and/or dietary self-monitoring
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mobile health tools (mobile phone apps, cellular body weight scales, text messaging)
Number of subjects: 96
Study: 30758653

Group type: EXPERIMENTAL
Intervention: ab interno subconjunctival gelatin implant (phaco + implant)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: ab interno subconjunctival gelatin implant (implant alone)
Number of subjects: 202
Study: 30758786

Group type: EXPERIMENTAL
Intervention: DAAs for 3 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no DAAs)
Number of subjects: 160
Study: 30758975

Group type: EXPERIMENTAL
Intervention: Arterial Vascular Pruning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right Ventricular Size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Outcomes
Number of subjects: 0
Study: 30759059

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30760013

Group type: EXPERIMENTAL
Intervention: Active psoriasis patients
Number of subjects: 20
Study: 30760105

Group type: EXPERIMENTAL
Intervention: Suppression of tumorigenicity-2
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-2
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Repeatedly measured biomarkers (suppression of tumorigenicity-2, galectin-3, galectin-4, growth differentiation factor-15, matrix metalloproteinase-2 and 9, tissue inhibitor metalloproteinase-4, perlecan, cathepsin-D, cystatin-B)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Biomarker trajectories
Number of subjects: 263
Study: 30760224

Group type: EXPERIMENTAL
Intervention: Intermittent auscultation augmented with fetal scalp stimulation (N=267)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Intermittent auscultation alone (N=251)
Number of subjects: 568
Study: 30760246

Group type: EXPERIMENTAL
Intervention: Objective physical activity measured by GT3X+ ActiGraph
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Dietary measures based on a 24-h food recall
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Biomarkers measuring cancer risk (insulin resistance, inflammation, oxidative stress)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Environmental exposure calculated using static and dynamic measures
Number of subjects: 602
Study: 30760295

Group type: EXPERIMENTAL
Intervention: Moderate short-term hyperventilation (HV)
Number of subjects: 11
Study: 30760395

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) approach to parent training
Number of subjects: 11
Study: 30760451

Group type: EXPERIMENTAL
Intervention: Thalidomide-cyclophosphamide-prednisone (TCP) regimen
Number of subjects: 25
Study: 30760466

Group type: EXPERIMENTAL
Intervention: Pracinostat 60 mg/d, 3 d/wk for 3 consecutive weeks plus azacitidine 75 mg/m²
Number of subjects: 0
Study: 30761059

Group type: EXPERIMENTAL
Intervention: Adapted cognitive behavioral treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 30761066

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) systems with different kinds of interaction devices
Number of subjects: 0
Study: 30761076

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0
Study: 30761078

Group type: EXPERIMENTAL
Intervention: Smart Device System (SDS) for multi-modal high-resolution acceleration measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smart Device System (SDS) including smartphone-based questionnaires, two smartwatches, and tablet-based Archimedean spirals drawing
Number of subjects: 0
Study: 30761278

Group type: EXPERIMENTAL
Intervention: Increasing PEEP (Positive End-Expiratory Pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30761601

Group type: EXPERIMENTAL
Intervention: fMRI version of the Suicide Implicit Association Task (S-IAT)
Number of subjects: 28
Study: 30762084

Group type: EXPERIMENTAL
Intervention: Gefitinib exposure at the time of ILD occurrence
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Gefitinib exposure
Number of subjects: 336
Study: 30762508

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg once daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 30762582

Group type: COMPARATOR
Intervention: Fitbit Charge alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fitbit Charge with MI and habit education
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Habit development
Number of subjects: 91
Study: 30762916

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Expert review of POCUS images
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POCUS parameters for small-bowel dilation ≥ 25 mm
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POCUS parameters for abnormal peristalsis
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POCUS parameters for transition point
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Expert review parameters for transition point
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POCUS parameters for intraperitoneal free fluid
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Expert review parameters for intraperitoneal free fluid
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: POCUS parameters for bowel wall edema
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Expert review parameters for bowel wall edema
Number of subjects: 217
Study: 30763338

Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by nab-paclitaxel (with trastuzumab if HER2-amplified)
Number of subjects: 51
Study: 30764641

Group type: EXPERIMENTAL
Intervention: 320-slice CTA
Number of subjects: 381
Study: 30764644

Group type: EXPERIMENTAL
Intervention: Charcoal-heated hookah smoking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrically heated hookah smoking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% CO gas mixture inhalation
Number of subjects: 30
Study: 30764654

Group type: COMPARATOR
Intervention: SDM tool with coaching
Number of subjects: 581

Group type: COMPARATOR
Intervention: SDM tool without coaching
Number of subjects: 581

Group type: COMPARATOR
Intervention: SDM tool (with or without coaching)
Number of subjects: 581
Study: 30764687

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2596

Group type: COMPARATOR
Intervention: Delay to hospital presentation of ≤120 minutes
Number of subjects: 2596

Group type: COMPARATOR
Intervention: Suboptimal post-PCI TIMI flow grade
Number of subjects: 2596
Study: 30764729

Group type: EXPERIMENTAL
Intervention: 3-month individualized, tailored PA counseling (face-to-face counseling and follow-up e-mail and telephone contacts)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3-month individualized, tailored PA counseling
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Step-based PA behavior change
Number of subjects: 300

Group type: COMPARATOR
Intervention: Reference group (no PA counseling)
Number of subjects: 300
Study: 30764793

Group type: EXPERIMENTAL
Intervention: HPP patients (regardless of prior or current treatment)
Number of subjects: 269
Study: 30764800

Group type: EXPERIMENTAL
Intervention: High indoxyl sulfate (IS) group (IS level ≥ 2.74 μg/ml)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Low indoxyl sulfate (IS) group (IS level < 2.74 μg/ml)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Indoxyl sulfate level ≥ 2.74 μg/ml
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis
Number of subjects: 94
Study: 30765035

Group type: EXPERIMENTAL
Intervention: Low coronary flow reserve
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Low coronary blood flow
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Decrease in cross-sectional area in response to IC acetylcholine
Number of subjects: 224

Group type: COMPARATOR
Intervention: Epicardial IC-nitroglycerin dilation
Number of subjects: 224
Study: 30765123

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals
Number of subjects: 9895

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 9895
Study: 30765258

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg and 10 mg/kg every 3 weeks) plus trastuzumab (6 mg/kg) in phase 1b
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Treatment-related death
Number of subjects: 58
Study: 30766449

Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Number of subjects: 150

Group type: COMPARATOR
Intervention: CROS hearing aids
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bone conduction (BC) device
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cochlear implantation (delayed insertion)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cochlear implantation (immediate insertion)
Number of subjects: 150
Study: 30766492

Group type: EXPERIMENTAL
Intervention: Vortioxetine, dosage and duration not available
Number of subjects: 0
Study: 30766508

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Upper Limb Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum Toxin
Number of subjects: 0
Study: 30766686

Group type: EXPERIMENTAL
Intervention: GEM (technology-assisted health coaching intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study: 30766706

Group type: EXPERIMENTAL
Intervention: Higher initial AMH concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women in the 3rd quartile of AMH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher AMH
Number of subjects: 0
Study: 30767112

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 11051
Study: 30767326

Group type: EXPERIMENTAL
Intervention: Probable cases (PTSD) identified with a threshold probability of 0.7
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Probable controls (without PTSD) identified with a threshold probability of 0.7
Number of subjects: 16000
Study: 30767353

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 30767431

Group type: EXPERIMENTAL
Intervention: cfDNA in plasma
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA in sputum
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA in urine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA from combination of plasma, sputum, and urine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA in sputum (smoking history)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA in sputum (no smoking history)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: cfDNA in plasma (smoking patients)
Number of subjects: 50
Study: 30767587

Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30767706

Group type: EXPERIMENTAL
Intervention: Isoniazid (dosage not specified)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Rifampicin (dosage not specified)
Number of subjects: 172
Study: 30767902

Group type: EXPERIMENTAL
Intervention: Internet-based training program and practice implementation toolkit with face-to-face training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Internet-based training program and practice implementation toolkit without face-to-face training
Number of subjects: 100
Study: 30767903

Group type: EXPERIMENTAL
Intervention: Web-accessible game intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control condition (list of SGMY-inclusive resources)
Number of subjects: 240
Study: 30768407

Group type: EXPERIMENTAL
Intervention: Sertraline for 12 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study: 30768457

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 263

Group type: COMPARATOR
Intervention: No epidural analgesia (Control)
Number of subjects: 263
Study: 30768838

Group type: EXPERIMENTAL
Intervention: elbasvir/grazoprevir treatment after recipient HCV was first detected
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HCV-infected hearts transplantation
Number of subjects: 10
Study: 30769292

Group type: EXPERIMENTAL
Intervention: Invasive mould infections (IMIs)
Number of subjects: 398
Study: 30770054

Group type: EXPERIMENTAL
Intervention: Night-time surgery
Number of subjects: 9861
Study: 30770207

Group type: EXPERIMENTAL
Intervention: Goals-of-care conversations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best practices for serious illness communication
Number of subjects: 0
Study: 30770221

Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine (120 μg) administered in various schedules (0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Booster dose of MenB-FHbp vaccine administered 48 months after primary vaccination
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Safety evaluations during booster stage
Number of subjects: 465
Study: 30770310

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 5 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 10 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 20 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 24
Study: 30770324

Group type: EXPERIMENTAL
Intervention: Efavirenz-based cART
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-efavirenz-based cART
Number of subjects: 141
Study: 30770348

Group type: EXPERIMENTAL
Intervention: Navoximod (GDC-0919) in combination with PD-L1 inhibitor Atezolizumab
Number of subjects: 0
Study: 30770354

Group type: EXPERIMENTAL
Intervention: Telemedicine eye screening (visit 1)
Number of subjects: 906
Study: 30770362

Group type: EXPERIMENTAL
Intervention: PD-L1 expression on myeloid cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-L1 expression on tumor cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation with macrophage gene expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 0
Study: 30770394

Group type: EXPERIMENTAL
Intervention: Patients with low VWF
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy controls (O blood group-matched)
Number of subjects: 110
Study: 30770421

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous brachial plexus PNS stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 30770528

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) testing with normal aLBC
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) testing with low-grade SILs (LSILs)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Composite endpoint of aLBC/HR-HPV testing
Number of subjects: 426
Study: 30770534

Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (106 TCID50)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (107 TCID50)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (any dose)
Number of subjects: 37
Study: 30770543

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Serum Ferritin (SF)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Soluble Transferrin Receptor (sTfR)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Hepcidin
Number of subjects: 234

Group type: COMPARATOR
Intervention: IL-6 and CRP (inflammation markers)
Number of subjects: 234
Study: 30770765

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 480

Group type: COMPARATOR
Intervention: Rheumatic diseases (SSc, RA, SLE, SjS)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Higher modified Rodnan skin scores (mRSS) in SSc patients
Number of subjects: 480
Study: 30771036

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 311

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 311
Study: 30771200

Group type: EXPERIMENTAL
Intervention: DSF/Cu (disulfiram and copper) plus standard monthly temozolomide (TMZ) 80 mg PO TID and Cu 1.5 mg PO TID
Number of subjects: 23
Study: 30771702

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A; Dysport®)
Number of subjects: 273
Study: 30771794

Group type: EXPERIMENTAL
Intervention: DULK score, serum CRP, serum PCT
Number of subjects: 0
Study: 30772227

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction (HFpEF) subjects
Number of subjects: 140
Study: 30772387

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk calculator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 three-category score
Number of subjects: 0

Group type: COMPARATOR
Intervention: COMPERA risk assessment strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: FPHR risk assessment strategy
Number of subjects: 0
Study: 30772588

Group type: EXPERIMENTAL
Intervention: Comprehensive training program for real-time optical diagnosis of colorectal polyps.
Number of subjects: 15
Study: 30772821

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cooled radiofrequency ablation (CRFA) after intra-articular steroid injection (IAS)
Number of subjects: 67
Study: 30772864

Group type: EXPERIMENTAL
Intervention: Vaccination against five vaccine targets (pneumococcus, hepatitis B virus, etc.), specific details on dosage and duration not available.
Number of subjects: 0
Study: 30772905

Group type: EXPERIMENTAL
Intervention: Purified anthocyanins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wild blueberries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control drinks (fiber, minerals, vitamins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily wild blueberry consumption for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthocyanin plasma metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of anthocyanin metabolites in mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily wild blueberry consumption
Number of subjects: 0
Study: 30772952

Group type: EXPERIMENTAL
Intervention: Migraine patients (n=52)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Non-migraine patients (n=594)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Migraine patients with aura
Number of subjects: 646
Study: 30773021

Group type: EXPERIMENTAL
Intervention: Inhibition of S-Adenosylhomocysteine Hydrolase (SAHH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30773025

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: Number of coronary arteries diseased
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: Severity of ischemia
Number of subjects: 2287
Study: 30773077

Group type: EXPERIMENTAL
Intervention: Alemtuzumab combined with CHOP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30773100

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study: 30773118

Group type: EXPERIMENTAL
Intervention: Cognitive impairment patients (Montreal Cognitive Assessment score <26) at baseline
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cognitive decline (Montreal Cognitive Assessment score drop by ≥2 points) at 1 year
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Recurrent myocardial infarction
Number of subjects: 298
Study: 30773459

Group type: EXPERIMENTAL
Intervention: HEU children
Number of subjects: 884

Group type: COMPARATOR
Intervention: HU children
Number of subjects: 884
Study: 30773463

Group type: EXPERIMENTAL
Intervention: BCL-2 inhibitor ABT-199
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of heme biosynthesis
Number of subjects: 0
Study: 30773970

Group type: EXPERIMENTAL
Intervention: IHC support intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strategies used by IHCs
Number of subjects: 25
Study: 30774324

Group type: EXPERIMENTAL
Intervention: 3-minute chair rise test (3-minute CRT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DIRECT questionnaire
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: endurance exercise test
Number of subjects: 116
Study: 30774388

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W, first three doses Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30774399

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT; antibiotics administered ≤48 hours post-initiation of antibiotic therapy)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT)
Number of subjects: 385
Study: 30774635

Group type: EXPERIMENTAL
Intervention: Liposome-based vaccines
Number of subjects: 0
Study: 30774953

Group type: EXPERIMENTAL
Intervention: Extended Cox Model analysis of exacerbation risk factors
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Spirometry in primary care
Number of subjects: 1247
Study: 30775698

Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle A used in the morning for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle B used in the evening for 8 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle A and B)
Number of subjects: 10